These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 19819089

  • 1. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, Ruiz-Requena ME, Escobar-Jiménez F.
    Maturitas; 2009 Nov 20; 64(3):188-92. PubMed ID: 19819089
    [Abstract] [Full Text] [Related]

  • 2. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
    Meier C, Meinhardt U, Greenfield JR, De Winter J, Nguyen TV, Dunstan CR, Seibel MJ.
    Clin Lab; 2006 Nov 20; 52(1-2):1-10. PubMed ID: 16506358
    [Abstract] [Full Text] [Related]

  • 3. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 Nov 20; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 20; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec 20; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 7. Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women.
    Adolf D, Wex T, Jahn O, Riebau C, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S, Piatek S.
    Maturitas; 2012 Feb 20; 71(2):169-72. PubMed ID: 22197348
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women.
    Wu N, Wang QP, Li H, Wu XP, Sun ZQ, Luo XH.
    Clin Chim Acta; 2010 May 02; 411(9-10):771-5. PubMed ID: 20184866
    [Abstract] [Full Text] [Related]

  • 13. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S, Adolf D, Wex T, Halangk W, Klose S, Westphal S, Amthauer H, Winckler S.
    Maturitas; 2013 Apr 02; 74(4):363-8. PubMed ID: 23391500
    [Abstract] [Full Text] [Related]

  • 14. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A, Piccione E.
    J Obstet Gynaecol Res; 2009 Feb 02; 35(1):152-9. PubMed ID: 19215563
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD.
    J Bone Miner Res; 1996 Mar 02; 11(3):337-49. PubMed ID: 8852944
    [Abstract] [Full Text] [Related]

  • 19. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
    Gur A, Colpan L, Cevik R, Nas K, Jale Sarac A.
    Clin Biochem; 2005 Jan 02; 38(1):66-72. PubMed ID: 15607319
    [Abstract] [Full Text] [Related]

  • 20. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.
    Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD.
    J Bone Miner Res; 2003 Oct 02; 18(10):1789-94. PubMed ID: 14584889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.